BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...
Low-dose colchicine reduces not only MACE but also MI, stroke, and the need for coronary revascularization among patients with known CAD, according to a new meta-analysis that sought to better tease ...
BASEL, SWITZERLAND — The anti-inflammatory agent colchicine failed to show significant benefit in the treatment of patients with non-cardioembolic ischemic stroke in the primary analysis of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results